GLUCOTRACK INC (GCTK) Stock Price, Forecast & Analysis
USA - NASDAQ:GCTK - US45824Q8042 - Common Stock
GCTK Key Statistics, Chart & Performance
The current stock price of GCTK is 5.7 USD. In the past month the price decreased by -20.17%. In the past year, price decreased by -98.25%.
GCTK Latest News, Press Relases and Analysis
GCTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.45 | 221.04B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.45 | 205.11B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.75 | 151.88B | ||
| SYK | STRYKER CORP | 27.62 | 139.05B | ||
| IDXX | IDEXX LABORATORIES INC | 56.5 | 57.00B | ||
| BDX | BECTON DICKINSON AND CO | 13.11 | 54.18B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.14 | 50.00B | ||
| RMD | RESMED INC | 25.5 | 36.84B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.99 | 33.52B | ||
| PODD | INSULET CORP | 71.4 | 22.97B | ||
| DXCM | DEXCOM INC | 31.25 | 22.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About GCTK
Company Profile
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Company Info
GLUCOTRACK INC
301 Rt 17 North, Suite 800
Rutherford NEW JERSEY US
Employees: 11
Phone: 197286757878
GLUCOTRACK INC / GCTK FAQ
What does GLUCOTRACK INC do?
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Can you provide the latest stock price for GLUCOTRACK INC?
The current stock price of GCTK is 5.7 USD. The price increased by 2.52% in the last trading session.
Does GCTK stock pay dividends?
GCTK does not pay a dividend.
How is the ChartMill rating for GLUCOTRACK INC?
GCTK has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does GLUCOTRACK INC belong to?
GLUCOTRACK INC (GCTK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the short interest for GCTK stock?
The outstanding short interest for GLUCOTRACK INC (GCTK) is 7.23% of its float.
GCTK Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GCTK. When comparing the yearly performance of all stocks, GCTK is a bad performer in the overall market: 96.54% of all stocks are doing better.
GCTK Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GCTK. GCTK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GCTK Financial Highlights
Over the last trailing twelve months GCTK reported a non-GAAP Earnings per Share(EPS) of -2312.58. The EPS increased by 20.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -262.19% | ||
| ROE | -389.1% | ||
| Debt/Equity | 0.03 |